These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 33024398)

  • 21. PARVB and HSD17B13 variants are associated with nonalcoholic fatty liver disease in children.
    Lee KJ; Moon JS; Lim JG; Huh H; Ahn JE; Kim L; Kim NY; Ko JS
    J Gastroenterol Hepatol; 2024 Jun; 39(6):1172-1182. PubMed ID: 38418429
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The common PNPLA3 variant p.I148M is associated with liver fat contents as quantified by controlled attenuation parameter (CAP).
    Arslanow A; Stokes CS; Weber SN; Grünhage F; Lammert F; Krawczyk M
    Liver Int; 2016 Mar; 36(3):418-26. PubMed ID: 26264356
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combined effects of the PNPLA3 rs738409, TM6SF2 rs58542926, and MBOAT7 rs641738 variants on NAFLD severity: a multicenter biopsy-based study.
    Krawczyk M; Rau M; Schattenberg JM; Bantel H; Pathil A; Demir M; Kluwe J; Boettler T; Lammert F; Geier A;
    J Lipid Res; 2017 Jan; 58(1):247-255. PubMed ID: 27836992
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High Risk of Fatty Liver Disease Amplifies the Alanine Transaminase-Lowering Effect of a HSD17B13 Variant.
    Gellert-Kristensen H; Nordestgaard BG; Tybjaerg-Hansen A; Stender S
    Hepatology; 2020 Jan; 71(1):56-66. PubMed ID: 31155741
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combining I148M and E167K variants to improve risk prediction for nonalcoholic fatty liver disease in Qingdao Han population, China.
    Chen LZ; Ding HY; Liu SS; Liu Q; Jiang XJ; Xin YN; Xuan SY
    Lipids Health Dis; 2019 Feb; 18(1):45. PubMed ID: 30738435
    [TBL] [Abstract][Full Text] [Related]  

  • 26.
    Kalinowski P; Smyk W; Nowosad M; Paluszkiewicz R; Michałowski Ł; Ziarkiewicz-Wróblewska B; Weber SN; Milkiewicz P; Lammert F; Zieniewicz K; Krawczyk M
    Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555467
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PNPLA3 rs738409 is associated with renal glomerular and tubular injury in NAFLD patients with persistently normal ALT levels.
    Sun DQ; Zheng KI; Xu G; Ma HL; Zhang HY; Pan XY; Zhu PW; Wang XD; Targher G; Byrne CD; Chen YP; Yuan WJ; Zheng MH
    Liver Int; 2020 Jan; 40(1):107-119. PubMed ID: 31519069
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined Effect of PNPLA3, TM6SF2, and HSD17B13 Variants on Risk of Cirrhosis and Hepatocellular Carcinoma in the General Population.
    Gellert-Kristensen H; Richardson TG; Davey Smith G; Nordestgaard BG; Tybjaerg-Hansen A; Stender S
    Hepatology; 2020 Sep; 72(3):845-856. PubMed ID: 32190914
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diagnosis of non-alcoholic fatty liver disease (NAFLD).
    Yki-Järvinen H
    Diabetologia; 2016 Jun; 59(6):1104-11. PubMed ID: 27091184
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Possible Relevance of PNPLA3 and TLL1 Gene Polymorphisms to the Efficacy of PEG-IFN Therapy for HBV-Infected Patients.
    Enomoto H; Aizawa N; Hasegawa K; Ikeda N; Sakai Y; Yoh K; Takata R; Yuri Y; Kishino K; Shimono Y; Ishii N; Takashima T; Nishimura T; Nishikawa H; Iwata Y; Iijima H; Nishiguchi S
    Int J Mol Sci; 2020 Apr; 21(9):. PubMed ID: 32349377
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genetic Determinants of Circulating Lipoproteins in Nonalcoholic Fatty Liver Disease.
    Jiang ZG; Tapper EB; Kim M; Connelly MA; Krawczyk SA; Yee EU; Herman MA; Mukamal KJ; Lai M
    J Clin Gastroenterol; 2018; 52(5):444-451. PubMed ID: 28362682
    [TBL] [Abstract][Full Text] [Related]  

  • 32. TM6SF2 E167K variant is associated with severe steatosis in chronic hepatitis C, regardless of PNPLA3 polymorphism.
    Coppola N; Rosa Z; Cirillo G; Stanzione M; Macera M; Boemio A; Grandone A; Pisaturo M; Marrone A; Adinolfi LE; Sagnelli E; Miraglia del Giudice E
    Liver Int; 2015 Aug; 35(8):1959-63. PubMed ID: 25581573
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PNPLA3 I148M gene variant and chronic kidney disease in type 2 diabetic patients with NAFLD: Clinical and experimental findings.
    Mantovani A; Taliento A; Zusi C; Baselli G; Prati D; Granata S; Zaza G; Colecchia A; Maffeis C; Byrne CD; Valenti L; Targher G
    Liver Int; 2020 May; 40(5):1130-1141. PubMed ID: 32125756
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort
    Anstee QM; Darlay R; Cockell S; Meroni M; Govaere O; Tiniakos D; Burt AD; Bedossa P; Palmer J; Liu YL; Aithal GP; Allison M; Yki-Järvinen H; Vacca M; Dufour JF; Invernizzi P; Prati D; Ekstedt M; Kechagias S; Francque S; Petta S; Bugianesi E; Clement K; Ratziu V; Schattenberg JM; Valenti L; Day CP; Cordell HJ; Daly AK;
    J Hepatol; 2020 Sep; 73(3):505-515. PubMed ID: 32298765
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Validation of PNPLA3 polymorphisms as risk factor for NAFLD and liver fibrosis in an admixed population.
    Mazo DF; Malta FM; Stefano JT; Salles APM; Gomes-Gouvea MS; Nastri ACS; Almeida JR; Pinho JRR; Carrilho FJ; Oliveira CP
    Ann Hepatol; 2019; 18(3):466-471. PubMed ID: 31054980
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association of HSD17B13 rs72613567:TA with non-alcoholic fatty liver disease in Hispanics/Latinos.
    Kallwitz E; Tayo BO; Kuniholm MH; Daviglus M; Zeng D; Isasi CR; Cotler SJ
    Liver Int; 2020 Apr; 40(4):889-893. PubMed ID: 31965669
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Physical activity and sedentary behavior can modulate the effect of the PNPLA3 variant on childhood NAFLD: a case-control study in a Chinese population.
    Wang S; Song J; Shang X; Chawla N; Yang Y; Meng X; Wang H; Ma J
    BMC Med Genet; 2016 Dec; 17(1):90. PubMed ID: 27905898
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Loss-of-function HSD17B13 variants, non-alcoholic steatohepatitis and adverse liver outcomes: Results from a multi-ethnic Asian cohort.
    Ting YW; Kong AS; Zain SM; Chan WK; Tan HL; Mohamed Z; Pung YF; Mohamed R
    Clin Mol Hepatol; 2021 Jul; 27(3):486-498. PubMed ID: 33618508
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treating liver fat and serum triglyceride levels in NAFLD, effects of PNPLA3 and TM6SF2 genotypes: Results from the WELCOME trial.
    Scorletti E; West AL; Bhatia L; Hoile SP; McCormick KG; Burdge GC; Lillycrop KA; Clough GF; Calder PC; Byrne CD
    J Hepatol; 2015 Dec; 63(6):1476-83. PubMed ID: 26272871
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genetic variant rs72613567 of HSD17B13 gene reduces alcohol-related liver disease risk in Chinese Han population.
    Chen H; Zhang Y; Guo T; Yang F; Mao Y; Li L; Liu C; Gao H; Jin Y; Che Y; Li Y; Huang J
    Liver Int; 2020 Sep; 40(9):2194-2202. PubMed ID: 33151633
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.